Latest Percutaneous coronary intervention Stories
Post-PASSION trial analysis confirms no major adverse cardiac events New research confirms thrombus aspiration (TA) during percutaneous coronary intervention (PCI) in patients with acute ST-segment elevation myocardial infarction (STEMI) provides long-term outcomes similar to conventional intervention with bare-metal or drug-eluting stents. Findings published in a special STEMI-focused issue of Catheterization and Cardiovascular Interventions, a journal of the Society for Cardiovascular...
CAESAREA, Israel, May 1, 2012 /PRNewswire/ -- CardioDex [http://www.cardiodex.com ] announces initial commercial use of a groundbreaking femoral access site closure device. Recent data from commercial use of the device on 41 patients at St Marien Hospital in Siegen Germany showed 100% success rate and no complications. "We are very excited about these new data that demonstrates that this device provides a viable treatment for a major unmet medical need due to the increasing...
Variation rates not fully explained by community rates for risk factors, heart attack, or cardiac mortality ANN ARBOR, Mich., April 30, 2012 /PRNewswire-USNewswire/ -- Regional differences in rates of cardiac procedures have increased in Michigan over the past decade--not fully explained by differences in health risk factors, heart attack or cardiac mortality rates--according to a report released today by the Center for Healthcare Research & Transformation (CHRT). The report...
NATICK, Mass., April 24, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announces CE Mark and European market launch of the Emerge(TM) PTCA[1] Dilatation Catheter. The Emerge Catheter is a next-generation pre-dilatation balloon catheter designed specifically to offer exceptional deliverability to address challenging lesions. The company plans to launch the product immediately in CE Mark countries in both Monorail® and Over-The-Wire (OTW) options. Commercial...
ABBOTT PARK, Ill. and ST. PAUL, Minn., April 23, 2012 /PRNewswire/ -- Abbott (NYSE: ABT) and St. Jude Medical (NYSE: STJ) today announced Choice Alliance, a multi-year joint initiative that provides mutual U.S. customers access to a robust portfolio of interventional cardiology, cardiac rhythm management, electrophysiology and intravascular imaging and diagnostic technologies. This enhanced alliance, which builds upon an existing agreement between the two companies that began in...
MILFORD, Mass., April 4, 2012 /PRNewswire/ -- PLC Systems Inc. (OTCBB: PLCSF), a company focused on innovative medical device technologies, today announced that results from a new investigator-sponsored clinical trial of RenalGuard(R) in Italy -- the first to follow longer-term outcomes -- were presented at the annual conference of the American College of Cardiology (ACC.12), March 24 - 27, 2012, Chicago, Illinois. These results showed that RenalGuard is superior to two alternative...
CHICAGO, April 3, 2012 /PRNewswire/ -- Despite treatment guidelines that favor optimal medical therapy, the number of patients hospitalized for coronary revascularization remains steady, according to a study conducted by Cardiac Data Solutions and presented at the recently completed American College of Cardiology 61st Scientific Sessions in Chicago. Approximately 25 million Americans are diagnosed with coronary heart disease (CHD), two million of whom are hospitalized each year....
Sleep deprivation does not disturb interventionist performance A single-center study found that percutaneous coronary intervention (PCI) procedures performed during the middle of the night do not adversely affect the safety and effectiveness of procedures performed the next day by the same operator. Findings now available in Catheterization and Cardiovascular Interventions, a journal published by Wiley-Blackwell on behalf of The Society for Cardiovascular Angiography and Interventions...
CHICAGO, March 29, 2012 /PRNewswire/ -- Incidences of renal complications, specifically acute renal failure (ARF) and new hemodialysis (HD), continue to increase significantly among Medicare beneficiaries (MB) admitted for percutaneous coronary intervention (PCI). While patients admitted with impaired renal function are at increased risk, approximately 10 percent of elective patients will suffer renal complications without prior indicators. These findings warrant more focus on...
Mount Sinai School of Medicine researchers presented 86 abstracts and plenary sessions at the American College of Cardiology’s (ACC) 61st Annual Scientific Session, including ground-breaking research on aggressive statin therapy, the prevalence of unrecognized cardiovascular disease symptoms in women, and morbidity associated with non-adherence to medication after stent implantation. New York, NY (PRWEB) March 28, 2012 Mount Sinai School of Medicine researchers presented 86 abstracts...
